Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Sara A. Hurvitz, Javier Cortés, Wei‐Pang Chung et al.|Cancer Research|2023Cited by 12